Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

REGN

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

REGN

AI Research Report

Powered by Claude

Ready to analyze REGN

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Biotech →
MRNA
Moderna
$42.80
+5.29%
LLY
Eli Lilly
$810.50
+2.30%
NVO
Novo Nordisk
—
—
BNTX
BioNTech
—
—
VRTX
Vertex Pharma
—
—
GILD
Gilead Sciences
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Biotechnology·NASDAQ NMS - GLOBAL MARKET·US·IPO 1991-04-02

Analyst Consensus

Buy
Based on 38 analysts
Period: 2026-04-01
30 Buy (79%)8 Hold (21%)0 Sell (0%)
Rating Distribution
Strong Buy
11
Buy
19
Hold
8
Sell
0
Strong Sell
0
Trend
2026-04
30/8/0
2026-03
27/9/0
2026-02
27/9/0
2026-01
26/9/1
📅 Earnings in 15d (Apr 29)
NASDAQ NMS - GLOBAL MARKETAfter-hours
Regeneron Pharmaceuticals Inc
Biotechnology
$754.58
$8.12 (+1.09%)
After-hrs · vs prev close $746.46
Open
$744.63
Prev close
$746.46
Day range
$743.71 – $756.48
52W range
$476.49 – $821.11
Mkt cap
$78.90B
P/E
17.6
EPS
$41.55
Beta
0.38

Fundamentals

Valuation
Market Cap
$78.90B
P/E (TTM)
17.61S&P avg ~22
P/S (TTM)
5.53S&P avg ~2.8
P/B
2.60S&P avg ~4.5
P/FCF
21.07S&P avg ~26
EPS (TTM)
$41.55
Book/sh
$295.71
Cash/sh
$81.41
Profitability
Gross Margin
86.56%avg ~45%
Operating Margin
24.95%avg ~15%
Net Margin
31.41%avg ~12%
ROE
14.83%avg ~18%
ROA
11.51%avg ~7%
ROI
13.61%
Payout Ratio
8.22%
FCF/sh
—
Growth & Health
Rev Growth YoY
0.99%
Rev Growth 5Y
11.04%
EPS Growth YoY
8.48%
EPS Growth 5Y
6.33%
Current Ratio
—
Quick Ratio
3.45
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.38
52W High
$821.11
52W Low
$476.49
Avg Vol (10D)
665.8K
Avg Vol (3M)
774.0K
Div Yield
0.50%
Div/sh (TTM)
—
Analyst
Buy (38)
Price Performance
5D-1.82%
MTD-3.39%
3M-6.81%
6M+27.50%
YTD-3.29%
1Y+36.62%

Factor Grades

View details →
B
Overall score: 69/100
B-
Valuation
C+
Growth
B+
Profitability
C+
Momentum
A
Financial Health
  • Yahoo·10h ago

    Why Telix Pharmaceuticals (ASX:TLX) Is Up 13.8% After Regeneron Radiopharma Alliance Announcement And What’s Next

    Earlier this month, Regeneron Pharmaceuticals and Telix Pharmaceuticals announced a collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies for solid tumors, combining Regeneron’s antibody platforms with Telix’s manufacturing and distribution network under a cost and profit-sharing model that begins with four programs and includes a US$40 million upfront payment. The agreement gives Telix the flexibility to either co-fund and share global profits or...

  • Benzinga·13h ago

    JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

    US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnings but missing sales estimates. Other stocks also down in pre-market trading.

  • Yahoo·1d ago

    SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria

    Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.

  • Yahoo·1d ago

    These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

    Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

  • Yahoo·1d ago

    Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies

    The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses.

  • Yahoo·1d ago

    Regeneron and Telix Announce Strategic Radiopharma Collaboration

    Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model Collaboration combines Regeneron’s leading antibody discovery/development platforms and oncology experience with Telix’s expertise in radiopharmaceutical development and manufacturing Telix to receive $40 million USD upfront for four initial programs with optionality to co-fund commercialization and profit-share, or earn up to an aggregate of $2.1 billion

  • Yahoo·1d ago

    Telix and Regeneron Announce Strategic Radiopharma Collaboration

    Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model.Collaboration combines Telix’s expertise in radiopharmaceutical development and manufacturing with Regeneron’s leading antibody discovery/development platforms and oncology experience. Telix to receive US$40 million upfront for four initial programs with optionality on a per program basis to co-fund commercialization and profit-share or earn up to an aggre

  • Benzinga·1d ago

    Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs

    Telix collaborates with Regeneron, targeting radiopharmaceutical development, with milestones up to $2.1 billion and royalties.

  • View all news →

Recent insider activity

View all →
  • 4OWNERSHIP DOCUMENT
    11d ago
  • 4PRIMARY DOCUMENT
    Mar 3
  • 4PRIMARY DOCUMENT
    Feb 23
  • 4PRIMARY DOCUMENT
    Feb 11
  • 4PRIMARY DOCUMENT
    Feb 11